Global Gastric Cancer Diagnostics Market is expected to grow with the CAGR of 6.8% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market

Global gastric cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global gastric cancer diagnostics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

• In August 2020, Vela Diagnostics announced that it has launched its new OncoKey SL 60 Plus Assay, which is a NGS based pan cancer test. This new product launched by the company has increased its credibility in the market leading to increased revenue in future

F. Hoffmann-La Roche Ltd is the dominating player in global Gastric cancer diagnostics market. The other key players existing in the market are bioMérieux SA, Myriad Genetics, Inc., GENERAL ELECTRIC COMPANY, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc. and QIAGEN, ACON Laboratories, Inc., Teco Diagnostics., Vela Diagnostics , Abbott, AdvaCare Pharma, MiRXES, Fujirebio ( An H.U. Group company), and Thermo Fisher Scientific Inc.

F. Hoffmann-La Roche Ltd

The company is founded in the year 1896, headquartered in Basel, Switzerland. The company is engaged in development and integration of diagnostic solutions to address healthcare challenges by offering in-vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation and IT and decision support solutions. The company operates in segment such as Pharmaceuticals, Solutions for Diagnostics, and Products for Researchers.

For instance,

• In April 2019, F. Hoffmann-La Roche Ltd announced that it has launched its new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer. This new product launched by the company has increased its sales in the market

The company has wide presence across Americas, Asia-Pacific, Europe, Middle East and Africa. The company also has various subsidiary companies including subsidiary are Genentech, Chugai Pharmaceutical Co., GenMark Diagnostics, Spark Therapeutics, Hoffman La Roche Limited, Flatiron Health, Inc., Kapa Biosystems Inc., and Ventana Medical Systems among others.

GENERAL ELECTRIC COMPANY

GENERAL ELECTRIC COMPANY founded in the year 1882, headquarter in Massachusetts, U.S. The company provides medical technologies, digital infrastructure, data analytics, and decision support tools that help healthcare professionals diagnose, treat, and monitor their patients. The company operates in equipment, pharmaceutical imaging agents, healthcare IT, pharmaceutical IT, command centers, consulting, services, accessories, finance, product security portal and virtual care solutions.

For instance,

• In August 2017, GE Healthcare (A subsidiary of GENERAL ELECTRIC COMPANY) announced strategic partnership with ARTMS Products, Inc. for the QUANTM99TM Irradiation System (QISTM) for radioisotope production. This strategic partnership done by the company increased its credibility in the market

The company has presence across Asia-Pacific, Europe, Middle East and Africa, South America, North America. The company also has various subsidiaries including GE healthcare, GE Aviation, GE Digital, GE Capital, Concept Laser GmbH, GE Research, Nuovo Pignone S.p.A.

bioMérieux SA

bioMérieux SA founded in the year 1963, headquartered in Marcy l’Étoile, France The company is engaged in providing solutions for the clinical field for diagnosing infectious diseases and in the industrial field for the detection of microorganisms in agri-food, pharmaceutical and cosmetic products. The company operates in Clinical Solutions and Industrial Microbiological Solutions.

The company has presence across North America, Europe, Middle East and Africa, Asia-Pacific, and South America. The company also has various subsidiaries including bioMérieux Algeria (Algeria), bioMérieux Benelux SA/NV (Belgium), bioMérieux Finland (Finland), bioMérieux Denmark APS (Denmark) and bioMérieux Italia S.p.A (Italy) among others.